| Detected | Trial | Change |
|---|---|---|
| 2026-05-28 | NCT06346392 AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-05-28 | NCT06346392 AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or… |
Trial sites reduced: 186 -> 158 locations |
| 2026-05-28 | NCT06346392 AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or… |
date change Primary completion pushed: 2026-05-14 -> 2026-06-15 |
| 2026-05-28 | NCT06346392 AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or… |
date change Completion pushed: 2026-09-14 -> 2026-10-14 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-10 | NCT07640048 Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study | Recruiting | |
| 2026-06-04 | NCT07627620 Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/… | Phase 2 | Not Yet Recruiting |
| 2026-06-03 | NCT07622797 Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as… | Phase 2 | Recruiting |
| 2026-06-01 | NCT07618546 A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With… | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT04342910 | Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With… | Gastric Cancer | Recruiting |
| NCT06239727 | Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment… | Nasopharyngeal Carcinoma | Recruiting |
| NCT04944914 | Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For… | Nasopharyngeal Carcinoma | Recruiting |
| NCT03907826 | PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma… | Recurrent Nasopharyngeal Carcinoma | Recruiting |
| NCT04639180 | A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in… | Hepatocellular Carcinoma (HCC) | Active, Not Recruiting |
| NCT07314203 | Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant… | Gastric Cancer | Not Yet Recruiting |
| NCT05198609 | Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal… | Hepatocellular Carcinoma | Active, Not Recruiting |
| NCT07371910 | Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced… | Metastatic Breast Cancer | Active, Not Recruiting |
| NCT06351020 | LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and… | Locally Advanced or Metastatic GC and GCJ Adenocarcinoma | Active, Not Recruiting |
| NCT06346392 | AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or… | Gastric Cancer | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT07309419 | A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus… | Hepatocellular Carcinoma | Not Yet Recruiting |
| NCT04208347 | Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for… | Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | Active, Not Recruiting |
| Phase 2 | |||
| NCT07334483 | A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy… | HCC | Recruiting |
| NCT07320586 | Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer | Gastric Cancer | Recruiting |
| NCT07527026 | A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course… | Locally Advanced Rectal Cancer | Recruiting |
| NCT07530094 | Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus… | Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | Recruiting |
| NCT07294664 | PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line… | Advanced Gastric Cancer | Recruiting |
| NCT07353684 | Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric… | Adebrelimab | Recruiting |
| NCT07569679 | Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for… | Biliary Tract Cancer | Recruiting |
| NCT05582499 | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study… | Breast Neoplasm | Recruiting |
| NCT07622797 | Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as… | Late-stage Resectable Esophageal Squamous Carcinoma | Recruiting |
| NCT06339619 | Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and… | Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma | Recruiting |
| NCT07312578 | Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of… | Esophageal Squamous Cell Carcinoma | Enrolling by Invitation |
| NCT07357532 | Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided… | Small Cell Lung Carcinoma | Not Yet Recruiting |
| NCT06693128 | Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for… | Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | Active, Not Recruiting |